NASDAQ:CALT

Calliditas Therapeutics AB (publ) News Headlines

$22.28
-0.43 (-1.89 %)
(As of 09/16/2021 12:00 AM ET)
Add
Compare
Today's Range
$22.23
$22.28
50-Day Range
$21.03
$32.53
52-Week Range
$20.50
$38.00
Volume30 shs
Average Volume33,061 shs
Market Capitalization$583.09 million
P/E RatioN/A
Dividend YieldN/A
Beta2.61

Media Mentions By Week

Calliditas Therapeutics AB (publ) Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

CALT
News Sentiment

0.42

0.30

Average
Medical
News Sentiment

Media Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

CALT Articles
This Week

6

1

CALT Articles
Average Week

Get Calliditas Therapeutics AB (publ) News Delivered to You Automatically

Sign up to receive the latest news and ratings for CALT and its competitors with MarketBeat's FREE daily newsletter.

Calliditas Therapeutics AB (publ) (NASDAQ CALT) News Headlines Today

SourceHeadline
Updated regulatory timeline for review of MAA in EuropeUpdated regulatory timeline for review of MAA in Europe
finance.yahoo.com - September 16 at 1:16 PM
53 Biggest Movers From Yesterday53 Biggest Movers From Yesterday
msn.com - September 16 at 8:16 AM
Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Sees Large Volume IncreaseCalliditas Therapeutics AB (publ) (NASDAQ:CALT) Sees Large Volume Increase
americanbankingnews.com - September 15 at 10:52 AM
Calliditas Therapeutics Stock Falls As FDA Pushes Nefecon PDUFA Goal Date To DecemberCalliditas Therapeutics Stock Falls As FDA Pushes Nefecon PDUFA Goal Date To December
finance.yahoo.com - September 15 at 10:04 AM
Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Shares Gap Down to $32.19Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Shares Gap Down to $32.19
americanbankingnews.com - September 10 at 11:29 AM
Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Shares Gap Up to $30.55Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Shares Gap Up to $30.55
americanbankingnews.com - September 9 at 11:06 AM
Calliditas Therapeutics AB - ADR Shares Close the Week 30.2% Higher - Weekly WrapCalliditas Therapeutics AB - ADR Shares Close the Week 30.2% Higher - Weekly Wrap
nasdaq.com - September 4 at 7:44 AM
Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Shares Gap Up to $26.55Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Shares Gap Up to $26.55
americanbankingnews.com - August 31 at 12:54 PM
Number of shares and votes in Calliditas TherapeuticsNumber of shares and votes in Calliditas Therapeutics
finance.yahoo.com - August 31 at 4:32 AM
Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Short Interest UpdateCalliditas Therapeutics AB (publ) (NASDAQ:CALT) Short Interest Update
americanbankingnews.com - August 31 at 2:58 AM
Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Shares Gap Down to $22.96Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Shares Gap Down to $22.96
americanbankingnews.com - August 24 at 10:54 AM
Calliditas Therapeutics: Interim Report Q2, 2021Calliditas Therapeutics: Interim Report Q2, 2021
finance.yahoo.com - August 19 at 2:07 AM
Calliditas Therapeutics has resolved on a directed share issue in the amount of 2.4 million shares, raising proceeds of approximately SEK 324 millionCalliditas Therapeutics has resolved on a directed share issue in the amount of 2.4 million shares, raising proceeds of approximately SEK 324 million
finance.yahoo.com - August 12 at 8:00 PM
Calliditas Therapeutics intends to carry out a directed share issueCalliditas Therapeutics intends to carry out a directed share issue
finance.yahoo.com - August 12 at 2:59 PM
Is a Surprise Coming for Calliditas (CALT) This Earnings Season?Is a Surprise Coming for Calliditas (CALT) This Earnings Season?
finance.yahoo.com - August 10 at 1:41 PM
Calliditas, STADA Ink Budesonide Commercialization Pact In Europe, UK For Immunoglobulin A NephropathyCalliditas, STADA Ink Budesonide Commercialization Pact In Europe, UK For Immunoglobulin A Nephropathy
finance.yahoo.com - July 21 at 2:54 PM
Calliditas Therapeutics and STADA partner to register and commercialize specialty therapy for IgA Nephropathy in EuropeCalliditas Therapeutics and STADA partner to register and commercialize specialty therapy for IgA Nephropathy in Europe
finance.yahoo.com - July 21 at 9:53 AM
Calliditas secures $75 million term loan facilityCalliditas secures $75 million term loan facility
finance.yahoo.com - July 15 at 9:00 AM
Calliditas Announces Submission of Marketing Authorisation Application for Nefecon to the European Medicines AgencyCalliditas Announces Submission of Marketing Authorisation Application for Nefecon to the European Medicines Agency
finance.yahoo.com - May 28 at 9:36 AM
Interim Report Q1, 2021Interim Report Q1, 2021
finance.yahoo.com - May 18 at 8:40 AM
Calliditas Therapeutics AB to Host Earnings CallCalliditas Therapeutics AB to Host Earnings Call
finance.yahoo.com - May 18 at 8:40 AM
Calliditas Therapeutics to host conference call to provide Business Update for the first quarter of 2021Calliditas Therapeutics to host conference call to provide Business Update for the first quarter of 2021
finance.yahoo.com - May 14 at 12:53 PM
Genkyotex Provides Business Update and Reports Cash Position at March 31, 2021Genkyotex Provides Business Update and Reports Cash Position at March 31, 2021
businesswire.com - May 13 at 9:35 PM
Calliditas promotes Andrew Udell to President, North AmericaCalliditas promotes Andrew Udell to President, North America
finance.yahoo.com - May 3 at 12:01 PM
FDA grants priority review for Nefecon, for patients with IgA nephropathyFDA grants priority review for Nefecon, for patients with IgA nephropathy
finance.yahoo.com - April 28 at 4:28 AM
Calliditas Therapeutics 2020 Annual Report PublishedCalliditas Therapeutics' 2020 Annual Report Published
finance.yahoo.com - April 27 at 12:30 PM
Calliditas Therapeutics AB: Change in financial calendarCalliditas Therapeutics AB: Change in financial calendar
finance.yahoo.com - April 27 at 12:30 PM
EMA Grants Accelerated Assessment Procedure for Nefecon for the Treatment of IgA NephropathyEMA Grants Accelerated Assessment Procedure for Nefecon for the Treatment of IgA Nephropathy
finance.yahoo.com - April 23 at 7:33 AM
Calliditas Therapeutics Files US Application For Nefecon In Kidney DiseaseCalliditas Therapeutics Files US Application For Nefecon In Kidney Disease
finance.yahoo.com - March 15 at 2:40 PM
Get Calliditas Therapeutics AB (publ) News Delivered to You Automatically

Sign up to receive the latest news and ratings for CALT and its competitors with MarketBeat's FREE daily newsletter.

This page was last updated on 9/16/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.